SG161234A1 - A method and composition for nutritionally improving glucose control and insulin action - Google Patents

A method and composition for nutritionally improving glucose control and insulin action

Info

Publication number
SG161234A1
SG161234A1 SG201002347-1A SG2010023471A SG161234A1 SG 161234 A1 SG161234 A1 SG 161234A1 SG 2010023471 A SG2010023471 A SG 2010023471A SG 161234 A1 SG161234 A1 SG 161234A1
Authority
SG
Singapore
Prior art keywords
composition
source
improving glucose
glucose control
insulin action
Prior art date
Application number
SG201002347-1A
Other languages
English (en)
Inventor
Kenneth C Hayes
Norman Alan Greenberg
John P Troup
Anne L Falk
Gianni Biolo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36661519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG161234(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG161234A1 publication Critical patent/SG161234A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
SG201002347-1A 2005-04-06 2006-04-04 A method and composition for nutritionally improving glucose control and insulin action SG161234A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66863305P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
SG161234A1 true SG161234A1 (en) 2010-05-27

Family

ID=36661519

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201002347-1A SG161234A1 (en) 2005-04-06 2006-04-04 A method and composition for nutritionally improving glucose control and insulin action

Country Status (16)

Country Link
US (2) US8067359B2 (enExample)
EP (3) EP2241195A1 (enExample)
JP (3) JP5788631B2 (enExample)
CN (2) CN101175416A (enExample)
AU (2) AU2006231557B2 (enExample)
BR (1) BRPI0608610A2 (enExample)
CA (1) CA2601427C (enExample)
DK (1) DK1868454T3 (enExample)
ES (1) ES2419205T3 (enExample)
IL (1) IL186005A0 (enExample)
MX (1) MX2007012450A (enExample)
PT (1) PT1868454E (enExample)
RU (1) RU2421076C2 (enExample)
SG (1) SG161234A1 (enExample)
WO (1) WO2006108008A2 (enExample)
ZA (1) ZA200707825B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283327B2 (en) 2005-03-19 2012-10-09 Kneller Bruce W Palatinose for enhancing dietary supplement and pharmaceutical delivery
CN101175416A (zh) * 2005-04-06 2008-05-07 诺瓦提斯公司 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物
AU2007267560B2 (en) * 2006-05-26 2010-10-21 Nestec S.A. Methods of use and nutritional compositions of Touchi Extract
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
US9511141B2 (en) * 2008-01-09 2016-12-06 Nutri Co., Ltd. Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
PT2294932E (pt) * 2008-05-07 2016-02-03 Vegenat S A Mistura de hidratos de carbono e a sua utilização para preparar um produto para nutrição oral ou entérica
WO2009135959A1 (es) * 2008-05-07 2009-11-12 Katry Inversiones, S.L. Producto alimenticio para la nutrición por vía enteral u oral del paciente diabético
EP2334377B1 (en) 2008-08-27 2016-05-04 PT. Dexa Medica Herbal extract as sensitivity enhancer toward insulin and antidiabetes
AU2009308152B2 (en) * 2008-10-21 2015-05-21 The General Hospital Corporation Cell transplantation
US8114445B2 (en) * 2008-11-07 2012-02-14 Reliv International Inc. Dietary supplement for promoting wellness and weight loss and methods of administering the same
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
CA2984935C (en) 2009-02-24 2021-01-12 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2411033B1 (en) 2009-03-24 2015-03-04 Universiti Putra Malaysia Anti-diabetic nutraceutical composition from palm leaf extract
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
MY173851A (en) * 2010-07-14 2020-02-25 Sudzucker Ag Mannheim/Ochsenfurt Isomaltulose for use in enhancing mental performance
JP6072684B2 (ja) 2010-08-06 2017-02-01 ザ ジェネラル ホスピタル コーポレーション ディー／ビー／エイ マサチューセッツ ジェネラル ホスピタル 細胞処置システムおよび細胞処置装置
CN101926431A (zh) * 2010-08-23 2010-12-29 贵阳高新创嘉创业服务有限公司 一种具有保健功能的组合物及其制备方法和用途
CN102007952A (zh) * 2010-09-26 2011-04-13 深圳职业技术学院 营养棒及其制备方法
SG2014011233A (en) * 2011-08-16 2014-06-27 Abbott Lab Nutritional compositions comprising a soluble viscous fiber and a polyphenol-containing plant extract
AU2013204445B2 (en) * 2012-03-13 2014-10-02 Sapporo Holdings Limited Nutritionally balanced food or beverage product
WO2013173719A1 (en) * 2012-05-18 2013-11-21 Metaproteomics, Llc Phytonutrient compositions and methods of use
JP6603133B2 (ja) 2013-02-06 2019-11-06 ブランダイス ユニバーシティー ヤシ果実を用いたｄｎａ損傷およびミトコンドリア機能障害の治療
RU2727960C2 (ru) * 2013-07-01 2020-07-28 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
AU2014353872B2 (en) * 2013-11-19 2020-05-14 Omniblend Innovation Pty Ltd Composition and method for control of post-prandial glucose
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CN106211757B (zh) * 2014-01-17 2022-06-07 康奈尔大学 使用维甲酸受体激动剂治疗代谢综合征相关病况的方法
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
CA3224535C (en) * 2016-01-12 2026-03-17 University Of Southern California A diet package for a fasting mimicking and enhancing diet
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
EP3468670B1 (en) 2016-06-10 2023-12-13 University of Copenhagen Predetermined diet for use in inducing weight loss and preventing weight gain
WO2017213961A1 (en) * 2016-06-10 2017-12-14 Gelesis Llc Methods of inducing weight loss, treating obesity and preventing weight gain
CN106490614A (zh) * 2016-10-31 2017-03-15 北京万源普达医疗科技有限公司 一种组合物及其作为糖尿病全营养配方食品的应用
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
WO2018222653A1 (en) 2017-06-01 2018-12-06 Gelesis Llc Compositions and methods for predicting and promoting weight loss
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP2022511693A (ja) * 2018-12-13 2022-02-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 動物における代謝健康を増進する方法
CN109528734A (zh) * 2019-01-24 2019-03-29 华纳时代健康科技（武汉）股份有限公司 一种复合营养组合物及其制备方法
CN110200276B (zh) * 2019-06-27 2023-04-07 刘东波 基于中药营养的组合物
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
WO2022049130A1 (en) 2020-09-01 2022-03-10 Shell Internationale Research Maatschappij B.V. Engine oil composition
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
CN113785915A (zh) * 2021-08-05 2021-12-14 中山大学 一种甜味敏感的食物配方及其动物模型的构建方法
CN113521277A (zh) * 2021-08-27 2021-10-22 四川力量科技有限公司 一种康复糖尿病的产品及其制备方法
CN116473125A (zh) * 2022-01-17 2023-07-25 内蒙古伊利实业集团股份有限公司 一种缓释碳水组合物以及应用
CN116549428B (zh) * 2023-06-20 2025-05-16 郑州大学 4-羟基异亮氨酸的新用途
WO2026038577A1 (ja) * 2024-08-15 2026-02-19 太陽化学株式会社 飲食品摂取後の血中アミノ酸または消化管ホルモン濃度制御用組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8317248D0 (en) * 1983-06-24 1983-07-27 Wyeth John & Brother Ltd Fat compositions
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
CA2173780A1 (en) * 1995-06-01 1996-12-02 Randy Grote Method for providing nutrition in a variety of compositional forms
MY115050A (en) * 1995-10-16 2003-03-31 Mead Johnson Nutrition Co Diabetic nutritional product having controlled absorption of carbohydrate
PT780055E (pt) * 1995-10-27 2003-04-30 Nestle Sa Composicao nutricional de cafe
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
ES2206821T3 (es) * 1997-06-23 2004-05-16 Societe Des Produits Nestle S.A. Uso de una composicion nutritiva para la preparacion de una composicion liquida para diabeticos.
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
JP2000264844A (ja) * 1999-01-11 2000-09-26 Otsuka Pharmaceut Factory Inc 腎疾患患者用栄養組成物
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
CN100456962C (zh) * 2001-02-09 2009-02-04 荷兰联合利华有限公司 含大豆蛋白和抑制素的食物制品
US6605310B2 (en) * 2001-06-06 2003-08-12 Nestec S.A. Calorically dense liquid oral supplement
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
WO2005013721A1 (en) * 2003-07-15 2005-02-17 Nestec S.A. High fibre high calorie liquid or powdered nutritional composition
CN101175416A (zh) * 2005-04-06 2008-05-07 诺瓦提斯公司 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物

Also Published As

Publication number Publication date
US8697630B2 (en) 2014-04-15
JP2013100353A (ja) 2013-05-23
US20080193603A1 (en) 2008-08-14
ZA200707825B (en) 2009-10-28
JP2015187182A (ja) 2015-10-29
JP5788631B2 (ja) 2015-10-07
WO2006108008A2 (en) 2006-10-12
US8067359B2 (en) 2011-11-29
EP1868454A2 (en) 2007-12-26
EP2243383A2 (en) 2010-10-27
IL186005A0 (en) 2008-01-20
JP2008535840A (ja) 2008-09-04
AU2006231557B2 (en) 2010-09-09
EP2243383A3 (en) 2011-02-16
CA2601427A1 (en) 2006-10-12
CN101175416A (zh) 2008-05-07
ES2419205T3 (es) 2013-08-19
DK1868454T3 (da) 2013-04-02
MX2007012450A (es) 2008-02-12
RU2007140731A (ru) 2009-05-20
EP2241195A1 (en) 2010-10-20
CA2601427C (en) 2013-06-11
CN105394748A (zh) 2016-03-16
US20110305791A1 (en) 2011-12-15
AU2006231557A1 (en) 2006-10-12
BRPI0608610A2 (pt) 2010-01-19
PT1868454E (pt) 2013-04-03
EP1868454B1 (en) 2013-03-06
WO2006108008A3 (en) 2007-01-18
HK1113289A1 (en) 2008-10-03
RU2421076C2 (ru) 2011-06-20
AU2010202933A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2006108008A3 (en) A method and composition for nutritionally improving glucose control and insulin action
WO2005023081A3 (en) Blood glucose level control
ES2171077T3 (es) Composicion para mejorar el metabolismo de la glucosa y de la insulina en animales de compañia.
WO2006083328A3 (en) Biologically active surfaces and methods of their use
WO2005119627A3 (en) Personal nutrition control devices
WO2006044531A3 (en) Antisense modulation of ptp1b expression
WO2006091589A3 (en) A coordinated health and human services delivery system and process
WO2005103002A3 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
WO2004089290A3 (en) Novel probiotic compositions and methods of using the same
TW200740379A (en) Nutrition for obese patients
AU2002353658A1 (en) Method of treating obesity, overweight, diabetes, or fluctuations in blood insuline or glucose levels
CY1108138T1 (el) Χρησιμοποιηση λουπινοκονγλουτινης δια την θεραπευτικη αγωγη διαβητου τυπου ιι
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
WO2006128125A3 (en) Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
IL172898A0 (en) Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus
WO2004024167A3 (fr) Utilisation de prebiotiques, preferentiellement le glucooligosaccharide, pour la prevention de l’installation du diabete de type ii
WO2009143065A3 (en) Rice bran extracts and methods of use thereof
WO2004069194A3 (en) Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
TW200501975A (en) An agent for upregulating physiological function during exercise
CY1115306T1 (el) Συνθεσεις και χρησεις αυτων
SI1753309T1 (sl) Živilski sestavki, ki vsebujejo kreatin
WO2007146559A3 (en) Nutritional composition and method of making the same
WO2005120553A3 (en) Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues
Waliszewski et al. Recovery of lysine and tryptophan from fortified nixtamalized cornflour and tortillas
WO2006004688A3 (en) Cookies comprising dietary fiber gel